Gene-lifestyle and Gene-Pharmacotherapy interactions in obesity and its cardiovascular consequences

Current Vascular Pharmacology

Volumn 9, Issue 4, 2011, Pages 401-456

  Franks, Paul W ^a,b   Poveda, Alaitz ^a,c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Gene x drug interaction; Gene x lifestyle interaction; Genetic; Nutriogenomics; Nutrition; Obesity; Pharmacogenetics; Physical activity

Indexed keywords

ACARBOSE; ADIPONECTIN; AMFEBUTAMONE; ANTIHYPERTENSIVE AGENT; CLOZAPINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; HALOPERIDOL; HEPATOCYTE NUCLEAR FACTOR 1BETA; HUMAN GROWTH HORMONE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; MANIFAXINE; METFORMIN; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; QUERCETIN; REPAGLINIDE; RISPERIDONE; ROSIGLITAZONE; SIBUTRAMINE; SIRTUIN 1; STAT3 PROTEIN; TRANSCRIPTION FACTOR 7 LIKE 2; TRANSCRIPTION FACTOR CLOCK; TROGLITAZONE; UNCOUPLING PROTEIN 2; UNCOUPLING PROTEIN 3; UNINDEXED DRUG;

AEROBIC EXERCISE; ALLELE; ANTIHYPERTENSIVE THERAPY; BODY MASS; DIABETES MELLITUS; DIET; FAT INTAKE; GENE INTERACTION; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GENETIC TRAIT; GENETIC VARIABILITY; GENOMICS; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GROWTH HORMONE DEFICIENCY; HETEROZYGOTE; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LIPID COMPOSITION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; OBESITY; PEDIGREE; PHYSICAL ACTIVITY; POPULATION GENETICS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT GAIN; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; GENETIC VARIATION; GENETICS, POPULATION; HUMANS; LIFE STYLE; OBESITY; PHARMACOGENETICS; WEIGHT LOSS;

EID: 79960025383     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111796197233     Document Type: Review

References (33)

1. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898-918.
2. Scuteri A, Sanna S, Chen WM, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genetics 2007; 3: e115.
3. Ordovas JM, Smith CE. Epigenetics and cardiovascular disease. Nature Rev 2010; 7: 510-9.
4. Pollack A. Walgreens Delays Selling Personal Genetic Test Kit. New York Times 2010 12 May 2010.
5. Franks PW, Nettleton JA. Gene x lifestyle interactions and complex disease traits--inferring cause and effect from observational data, sine qua non. Am J Epidemiol 2010; 172: 992-7; discussion 8-9.
6. Pomeroy J, Soderberg AM, Franks PW. Gene-lifestyle interactions and their consequences on human health. Med Sport Sci 2009; 54: 110-35.
7. Luan J, Browne PO, Harding AH, et al. Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 2001; 50: 686-9.
8. Memisoglu A, Hu FB, Hankinson SE, et al. Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Human Mol Genetics 2003; 12: 2923-9.
9. Tai ES, Corella D, Deurenberg-Yap M, et al. Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. L Lipid Res 2004; 45: 674-85.
10. Nelson TL, Fingerlin TE, Moss LK, Barmada MM, Ferrell RE, Norris JM. Association of the peroxisome proliferator-activated receptor gamma gene with type 2 diabetes mellitus varies by physical activity among non-Hispanic whites from Colorado. Metabolism 2007; 56: 388-93.
11. Palla L, Higgins JP, Wareham NJ, Sharp SJ. Challenges in the use of literature-based meta-analysis to examine gene-environment interactions. Am J Epidemiol 2010; 171: 1225-32.
12. Franks PW, Luan J, Browne PO, et al. Does peroxisome proliferator-activated receptor gamma genotype (Pro12ala) modify the association of physical activity and dietary fat with fasting insulin level? Metabolism: Clin Exp 2004; 53: 11-6.
13. Kahara T, Takamura T, Hayakawa T, et al. PPARgamma gene polymorphism is associated with exercise-mediated changes of insulin resistance in healthy men. Metabolism 2003; 52: 209-12.
14. Adamo KB, Sigal RJ, Williams K, Kenny G, Prud'homme D, Tesson F. Influence of Pro12Ala peroxisome proliferator-activated receptor gamma2 polymorphism on glucose response to exercise training in type 2 diabetes. Diabetologia 2005; 48: 1503-9.
15. Weiss EP, Kulaputana O, Ghiu IA, et al. Endurance traininginduced changes in the insulin response to oral glucose are associated with the peroxisome proliferator-activated receptor-gamma2 Pro12Ala genotype in men but not in women. Metabolism 2005; 54: 97-102.
16. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
17. Lindi VI, Uusitupa MI, Lindstrom J, et al. Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 2002; 51: 2581-6.
18. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
19. Florez JC, Jablonski KA, Sun MW, et al. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 2007; 92: 1502-9.
20. Franks PW, Jablonski KA, Delahanty L, et al. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia 2007; 50: 2451-60.
21. Kilpelainen TO, Lakka TA, Laaksonen DE, et al. SNPs in PPARG associate with type 2 diabetes and interact with physical activity. Med Sci Sports Exerc 2008; 40: 25-33.
22. Otabe S, Clement K, Dina C, et al. A genetic variation in the 5' flanking region of the UCP3 gene is associated with body mass index in humans in interaction with physical activity. Diabetologia 2000; 43: 245-9.
23. Berentzen T, Dalgaard LT, Petersen L, Pedersen O, Sorensen TI. Interactions between physical activity and variants of the genes encoding uncoupling proteins-2 and-3 in relation to body weight changes during a 10-y follow-up. Int J Obes (Lond) 2005; 29: 93-9.
24. Andreasen CH, Stender-Petersen KL, Mogensen MS, et al. Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes 2008; 57: 95-101.
25. Rampersaud E, Mitchell BD, Pollin TI, et al. Physical activity and the association of common FTO gene variants with body mass index and obesity. Arch Intern Med 2008; 168: 1791-7.
26. Li S, Zhao JH, Luan J, et al. Physical activity attenuates the genetic predisposition to obesity in 20,000 men and women from EPICNorfolk prospective population study. PLoS Med 2010; 7.
27. Liu YR, Loh EW, Lan TH, et al. ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics. Pharmacogenomics J 2010; 10: 30-9.
28. Le Hellard S, Theisen FM, Haberhausen M, et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol Psychiat 2009; 14: 308-17.
29. Herbert A, Gerry NP, McQueen MB, et al. A common genetic variant is associated with adult and childhood obesity. Science (New York, NY) 2006; 312: 279-83.
30. Franks PW, Jablonski KA, Delahanty LM, et al. Assessing genetreatment interactions at the FTO and INSIG2 loci on obesityrelated traits in the Diabetes Prevention Program. Diabetologia 2008; 51: 2214-23.
31. Hu J, Redden DT, Berrettini WH, et al. No evidence for a major role of polymorphisms during bupropion treatment. Obesity (Silver Spring, MD) 2006; 14: 1863-7.
32. Skelly T, Pinheiro AP, Lange LA, Sullivan PF. Is rs7566605, a SNP near INSIG2, associated with body mass in a randomized clinical trial of antipsychotics in schizophrenia? Mol Psychiat 2007; 12: 321-2.
33. Zacharova J, Chiasson JL, Laakso M. Leptin receptor gene variation predicts weight change in subjects with impaired glucose tolerance. Obesity Res 2005; 13: 501-6.